SCHEMBL7511028

SCHEMBL7511028

N#Cc1ccc2nc(-c3ccc(C=C4SC(=O)NC4=O)cc3)[nH]c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKN1 Q16512 1/20 0.55
PKN2 Q16513 1/20 0.55
CHEK2 O96017 2/20 0.52
DGAT1 O75907 1/20 0.47
SOAT1 P35610 1/20 0.47
KCNH2 Q12809 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ESRRA P11474 7/20 0.47
CISD1 Q9NZ45 3/20 0.46
PIK3CA P42336 2/20 0.46
PIK3CG P48736 2/20 0.46
PIK3CD O00329 1/20 0.46
NPC1 O15118 1/20 0.46
CSNK2A2 P19784 1/20 0.46
MAOB P27338 1/20 0.46
PIK3CB P42338 1/20 0.46
MTOR P42345 1/20 0.46
CLK1 P49759 1/20 0.46
RAB9A P51151 1/20 0.46
CSNK2B P67870 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7511024 0.91 TDP1 (0.47) PKN1PKN2CHEK2TDP1ESRRA
SCHEMBL7511020 0.91 TDP1 (0.47) PKN1PKN2CHEK2TDP1ESRRA
SCHEMBL7521939 0.80 PIM1 (0.60) DGAT1SOAT1KCNH2CISD1PIM1
SCHEMBL7511829 0.80 PIM1 (0.56) PKN1PKN2TDP1CISD1NPC1
SCHEMBL7511827 0.80 PIM1 (0.56) PKN1PKN2TDP1CISD1NPC1
SCHEMBL7516143 0.80 PIM1 (0.51) TDP1CISD1PIK3CAPIK3CGPIK3CD
SCHEMBL7511802 0.80 PIM1 (0.51) TDP1CISD1PIK3CAPIK3CGPIK3CD
SCHEMBL7516825 0.80 IGF1R (0.56) TDP1CISD1PIK3CAPIK3CGPIK3CD
SCHEMBL7511794 0.80 PIM1 (0.51) TDP1CISD1PIK3CAPIK3CGPIK3CD
SCHEMBL7516149 0.80 PIM1 (0.51) TDP1CISD1PIK3CAPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 PKN1 3109/4885PKN2 3637/4885CHEK2 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.